In response to a rash of reckless decisions by pharmaceutical companies, U.S. Representative Abigail Spanberger is leading a bipartisan effort to protect the 340B Drug Pricing Program and prevent additional…
By email dated January 14, 2022, Bristol Myers Squibb (BMS) announced that, effective March 1, 2022, it will implement a new 340B contract pharmacy policy impacting two drug categories: non-immunomodulatory…
In October 2021, Second Sight, the owner of 340B ESP, updated the Terms of Use (TOU) that covered entities must agree to when registering for the 340B ESP platform. There…
AbbVie is the 11th Manufacturer to Restrict Access to 340B Prices at Contract Pharmacies By letter dated December 29, 2021, AbbVie announced that, effective February 1, 2022, it will implement…